BiotonLTS:0DTR 68 EV-to-FCF is 90.95 as of Jul. 12, 2026, which is 569% above its 10-year median of 13.60. GuruFocus rates LTS:0DTR with a GF Score™ of 68/100 and a GF Value™ of zł4.24. The stock has 3 warning signs investors should review. Among 329 Biotechnology companies, Bioton ranks worse than 87.84% on this metric.
EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Bioton's Enterprise Value is zł385.0 Mil.
Bioton's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2026 was zł4.2 Mil. Therefore, Bioton's EV-to-FCF for today is 90.95.
The historical rank and industry rank for Bioton's EV-to-FCF or its related term are showing as below:
LTS:0DTR'
s EV-to-FCF Range Over the Past 10 Years
Min: -672.1 Med: 13.6 Max: 480.66
Current: 90.95
During the past 13 years, the highest EV-to-FCF of Bioton was 480.66. The lowest was -672.10. And the median was 13.60.
LTS:0DTR's EV-to-FCF is ranked worse than 87.84% of 329
companies
in the Biotechnology industry
Industry Median: 15.85
vs LTS:0DTR: 90.95
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
As of today (2026-07-12), Bioton's stock price is zł3.42829.
Bioton's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 was zł0.048. Therefore, Bioton's PE Ratio (TTM) for today is 71.42.
Bioton (LTS:0DTR) EV-to-FCF Explanation
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Bioton's share price for today is zł3.42829.
Bioton's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was zł0.048.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Bioton EV-to-FCF Related Terms
Bioton EV-to-FCF Historical Data
* Premium members only.
The historical data trend for Bioton's EV-to-FCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
LTS:0DTR vs VRTX, REGN, ALNY: EV-to-FCF Comparison
For the Biotechnology subindustry, Bioton's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Bioton EV-to-FCF vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Bioton's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where Bioton's EV-to-FCF falls into.
Bioton's current Enterprise Value is zł385.0 Mil.
Bioton's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was zł4.2 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Bioton (LTS:0DTR) has a EV-to-FCF of 90.95 as of Jul. 12, 2026. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Bioton and its competitors. This is 569% above median its historical median of 13.60. According to the industry distribution chart, Bioton ranks #289 out of 329 companies in the Biotechnology industry, placing it in the top 87.8%.
Is Bioton's EV-to-FCF too high?
Bioton's current EV-to-FCF of 90.95 is 569% above median its 10-year median of 13.60. The Biotechnology industry median EV-to-FCF is 15.85. Bioton's value of 90.95 is 473.8% above this industry median. Based on the distribution chart, Bioton ranks #289 out of 329 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Bioton has a GF Score™ of 68/100, reflecting its overall financial health beyond just this single metric.
How does Bioton's EV-to-FCF compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Bioton ranks #289 out of 329 companies for EV-to-FCF. This places Bioton in the lower half of its industry. The industry median EV-to-FCF is 15.85. Bioton's value of 90.95 is 473.8% above this benchmark. While the company's 10-year median is 13.60 vs. the industry median of 15.85, Bioton has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-FCF for a Biotechnology company?
The median EV-to-FCF among Biotechnology companies is 15.85, based on 329 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-FCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-FCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Bioton's current EV-to-FCF of 90.95 is 473.8% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-FCF mean?
A high EV-to-FCF can signal that a stock is expensive relative to its fundamentals. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Bioton and its competitors. For the Biotechnology industry, the median EV-to-FCF is 15.85 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Bioton's current EV-to-FCF is 90.95, which is 569% above median its own 10-year median of 13.60. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Bioton stock overvalued right now?
Bioton (LTS:0DTR) has a current EV-to-FCF of 90.95. The stock's GF Value™ is zł4.24, compared to a current price of zł3.43 — trading 19.1% below its estimated fair value. The current EV-to-FCF is 90.95, which is 569% above median its 10-year median of 13.60 and 473.8% above the Biotechnology industry median of 15.85. Bioton's overall GF Score™ is 68/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-FCF calculated?
EV-to-FCF is calculated from a company's financial statements. For Bioton (LTS:0DTR), the current EV-to-FCF is 90.95 as of Jul. 12, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Bioton (LTS:0DTR) Overvalued in 2026?
Based on GuruFocus' analysis, Bioton stock appears to be undervalued.
The current stock price of zł3.43 is trading 19.1% below its estimated GF Value™ of zł4.24.
Key valuation signals for LTS:0DTR:
EV-to-FCF: 90.95 (569% above median its 10-year median of 13.60)
GF Value™: zł4.24 vs. price of zł3.43 (19.1% below fair value)
Industry Position: 473.8% above the Biotechnology median (#289 of 329)
No single metric tells the full story. See the LTS:0DTR stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Bioton SA is a Poland based company engaged in the principal business activity of manufacturing medicines and pharmaceutical preparations and production of pharmaceutical substances. The products of the company include recombinant human insulin in pharmaceutical substance form and as preparations for injections; glimepiride, an oral hypoglycemic drug; and metformin, an oral hypoglycemic drug. Its products line focuses on diet supplements, products for particular nutritional uses and cosmetics dedicated to patients with certain health problems. The group operates in Poland and internationally, of which majority of the revenue is derived from Poland.
68GF Score
Get the complete analysis for LTS:0DTR
EV-to-FCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LTS:0DTR has been successfully added to your 
